Mesothelioma News and Research

RSS

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.

New report highlights global burden of pollution-related disease and death

Pollution is linked to an estimated nine million deaths each year worldwide – equivalent to one in six (16%) of all deaths, according to a major new report in The Lancet.

20 Oct 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

BWH researchers identify new rare genetic cause of peritoneal mesothelioma

Mesothelioma is a rare and aggressive tumor that, in many cases, results from exposure to asbestos. But over the last several decades, other causes of the disease have emerged, including treatment with high-intensity therapeutic radiation and, more recently, an inherited genetic mutation.

14 Sep 2017

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented today at the ESMO 2017 Congress in Madrid.

11 Sep 2017

Scientists reveal role of cellular prion protein in development of NF2-related tumors

New research published today, 10th July 2017, online in the journal Oncogene could offer hope to the thousands of, mainly young, people affected by the hereditary condition Neurofibromatosis 2 (NF2).

10 Jul 2017

New clinical trial offers hope for patients with hard-to-treat cancer caused by asbestos

Patients with a hard-to-treat type of cancer are being given new hope in a ground-breaking clinical trial. Researchers at the University of Southampton and the University of Leicester are trialing a drug that could boost the body's immune system to fight off mesothelioma, which can be caused by asbestos.

19 May 2017

Scientists establish process for identifying biomarkers for cancer diagnosis

Scientists at Ruhr-Universität Bochum have established a process for identifying biomarkers for the diagnosis of different types of cancer.

3 Apr 2017

Combination of TTFields with standard therapies may improve survival in pancreatic cancer patients

Novocure announced today results from the second cohort of its phase 2 pilot PANOVA trial studying Tumor Treating Fields (TTFields) in combination with nab-paclitaxel and gemcitabine for the treatment of advanced pancreatic cancer.

31 Mar 2017

Phase 2 study shows encouraging results for TTFields therapy in treating recurrent ovarian cancer

Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.

31 Mar 2017

New NCCN patient guide for Waldenström's Macroglobulinemia helps make informed treatment decisions

A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the United States each year. While it is not curable, Waldenström's Macroglobulinemia is slow growing, and in many patients, manageable as a chronic disease.

6 Feb 2017

NCCN publishes new easy-to-understand patient education resources focused on brain cancer

The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Gliomas—the first in a series of patient education resources focused on Brain Cancer.

10 Jan 2017

Global experts meet at IASLC 17th World Conference on Lung Cancer in Vienna

Global lung cancer researchers and patient advocates today emphasized that new models of delivering care and communicating about cancer care play an important role in the fight against lung cancer.

6 Dec 2016

D.C. Council passes ‘Death with Dignity Act’ by a veto-proof 11-2 margin

Compassion & Choices reports the District of Columbia is poised to become the seventh jurisdiction in the U.S. where medical aid in dying is authorized for terminally ill residents after the D.C. Council passed the D.C. Death with Dignity Act by a veto-proof 11-2 margin.

16 Nov 2016

Scientists identify genetic mutations in highly aggressive rhabdoid meningiomas

Meningiomas are the most common primary brain tumors, but the term encompasses over a dozen subtypes that range from benign to highly aggressive.

10 Nov 2016

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.

2 Nov 2016

Scientists discover new option for treating malignant pleural mesothelioma

Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma.

24 Oct 2016

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year.

4 Oct 2016

New NCCN Imaging AUC released for eight new cancers

The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types.

29 Aug 2016

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades.

14 Jul 2016

Novel combination therapy slows cancer growth in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors.

22 Jun 2016